278 related articles for article (PubMed ID: 25548095)
21. Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells.
Lim JY; Kim TW; Ryu DB; Park SS; Lee SE; Kim BS; Min CK
Cancer Immunol Res; 2021 May; 9(5):503-513. PubMed ID: 33771821
[TBL] [Abstract][Full Text] [Related]
22. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
Front Immunol; 2020; 11():613215. PubMed ID: 33679700
[TBL] [Abstract][Full Text] [Related]
23. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.
Huang H; Zhang G; Li G; Ma H; Zhang X
Tumour Biol; 2015 Sep; 36(10):7987-96. PubMed ID: 25967454
[TBL] [Abstract][Full Text] [Related]
24. Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90.
Boral B; Ballı HT; Sözütok S; Pehlivan UA; Aikimbaev K
Scand J Immunol; 2022 Mar; 95(3):e13132. PubMed ID: 34936119
[TBL] [Abstract][Full Text] [Related]
25. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.
Brimnes MK; Vangsted AJ; Knudsen LM; Gimsing P; Gang AO; Johnsen HE; Svane IM
Scand J Immunol; 2010 Dec; 72(6):540-7. PubMed ID: 21044128
[TBL] [Abstract][Full Text] [Related]
26. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.
Mougiakakos D; Jitschin R; von Bahr L; Poschke I; Gary R; Sundberg B; Gerbitz A; Ljungman P; Le Blanc K
Leukemia; 2013 Feb; 27(2):377-88. PubMed ID: 22828446
[TBL] [Abstract][Full Text] [Related]
28. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
29. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.
Xu XD; Hu J; Wang M; Peng F; Tian R; Guo XJ; Xie Y; Qin RY
Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):99-105. PubMed ID: 26818550
[TBL] [Abstract][Full Text] [Related]
30. CD14
Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
[TBL] [Abstract][Full Text] [Related]
31. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
32. CD1d is a novel cell-surface marker for human monocytic myeloid-derived suppressor cells with T cell suppression activity in peripheral blood after allogeneic hematopoietic stem cell transplantation.
An B; Lim JY; Jeong S; Shin DM; Choi EY; Min CK; Hong SH
Biochem Biophys Res Commun; 2018 Jan; 495(1):519-525. PubMed ID: 29108995
[TBL] [Abstract][Full Text] [Related]
33. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.
Schilling B; Sucker A; Griewank K; Zhao F; Weide B; Görgens A; Giebel B; Schadendorf D; Paschen A
Int J Cancer; 2013 Oct; 133(7):1653-63. PubMed ID: 23526263
[TBL] [Abstract][Full Text] [Related]
34. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
[TBL] [Abstract][Full Text] [Related]
35. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
[TBL] [Abstract][Full Text] [Related]
36. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
[TBL] [Abstract][Full Text] [Related]
37. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
38. In Vivo Mobilization and Functional Characterization of Nonhuman Primate Monocytic Myeloid-Derived Suppressor Cells.
Zahorchak AF; Ezzelarab MB; Lu L; Turnquist HR; Thomson AW
Am J Transplant; 2016 Feb; 16(2):661-71. PubMed ID: 26372923
[TBL] [Abstract][Full Text] [Related]
39. The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.
Franssen LE; van de Donk NW; Emmelot ME; Roeven MW; Schaap N; Dolstra H; Hobo W; Lokhorst HM; Mutis T
Bone Marrow Transplant; 2015 Jun; 50(6):822-8. PubMed ID: 25798669
[TBL] [Abstract][Full Text] [Related]
40. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.
Kitano S; Postow MA; Ziegler CG; Kuk D; Panageas KS; Cortez C; Rasalan T; Adamow M; Yuan J; Wong P; Altan-Bonnet G; Wolchok JD; Lesokhin AM
Cancer Immunol Res; 2014 Aug; 2(8):812-21. PubMed ID: 24844912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
